Pliant Therapeutics (Nasdaq: PLRX) has announced positive top-line data from a 12-week, mid-stage trial of bexotegrast, code name PLN-74809.
The Californian company is developing the small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
IPF is a chronic, progressive lung disease characterized by the thickening and scarring of the lung tissue, inhibiting lung function.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze